iXCells Delivers 500+ Characterized iPSC Lines for Global Biotechnology Company

iXCells Biotechnologies USA Inc., a provider of human cell-based solutions and custom iPSC services, has delivered over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company.

The collaboration leverages iXCells’ iPSCore platform, which enables the large-scale generation of well-characterized patient-derived iPSC lines, to support the discovery and development of novel therapeutics.

To date, iXCells has delivered more than 500 characterized patient-derived iPSC lines under the collaboration, with more than 700 additional lines in development, demonstrating the scalability and efficiency of the iPSCore platform. The collaboration demonstrates iXCells’ ability to deliver iPSC reprogramming at industrial scale, enabling high-throughput production of large volumes of patient-derived lines while maintaining quality, reproducibility, and consistency. Further projects as part of the collaboration will expand the scale of the platform, including for differentiated cell types and disease-relevant models.

Steve Smith, CEO at iXCells Biotechnologies, said: “Reliable, large-scale access to patient-relevant cell models is revolutionizing our approach to disease research. By reaching this milestone in our collaboration, we are demonstrating that the right expertise and infrastructure can empower discovery teams to leverage diverse data from the very start, enabling delivering iPSC models at scale and dramatically improving the likelihood of successful drug development. Ongoing expansion of our iPSCore platform capabilities will enable large-scale access to high quality patient-derived human cell models to drive breakthroughs in drug discovery.”